Abstract:Background Integrin αvβ6 is a heterodimeric cell surface protein whose cellular expression is determined by the availability of the integrin β6 subunit (ITGB6). It is expressed at very low levels in most organs during tissue homeostasis but shows highly upregulated expression during the process of tumorigenesis in many cancers of epithelial origin. Notably, enhanced expression of integrin αvβ6 is associated with aggressive disease and poor prognosis in numerous carcinoma entities. Integrin αvβ6 is one of the major physiological activators of transforming growth factor-β (TGF-β), which has been shown to inhibit the antitumor T-cell response and cause resistance to immunotherapy in mouse models of colorectal and mammary cancer. In this study, we investigated the effect of ITGB6 expression and antibody-mediated integrin αvβ6 inhibition on the tumor immune response in colorectal cancer. Methods Using orthotopic and heterotopic tumor cell injection, we assessed the effect of ITGB6 on tumor growth and tumor immune response in wild type mice, mice with defective TGF-β signaling, and mice treated with anti-integrin αvβ6 antibodies. To examine the effect of ITGB6 in human colorectal cancer, we analyzed RNAseq data from the colon adenocarcinoma dataset of The Cancer Genome Atlas (TCGA-COAD). Results We demonstrate that expression of ITGB6 is an immune evasion strategy in colorectal cancer, causing inhibition of the antitumor immune response and resistance to immune checkpoint blockade therapy by activating latent TGF-β. Antibody-mediated inhibition of integrin αvβ6 sparked a potent cytotoxic T-cell response and overcame resistance to programmed cell death protein 1 (PD-1) blockade therapy in ITGB6 expressing tumors, provoking a drastic increase in anti-PD-1 treatment efficacy. Further, we show that the majority of tumors in patients with colorectal cancer express sufficient ITGB6 to provoke inhibition of the cytotoxic T-cell response, indicating that most patients could benefit from integrin αvβ6 blockade therapy. Conclusions These findings propose inhibition of integrin αvβ6 as a promising new therapy for colorectal cancer, which blocks tumor-promoting TGF-β activation, prevents tumor exclusion of cytotoxic T-cells and enhances the efficacy of immune checkpoint blockade therapy.

Figure S5 from Integrin β7 Inhibits Colorectal Cancer Pathogenesis via Maintaining Antitumor Immunity

Supplementary Figure S6 from <i>fusobacterium Nucleatum</i> Subspecies <i>animalis</i> Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors

Supplementary Figures S1-S8 from <i>a. Muciniphila</i> Suppresses Colorectal Tumorigenesis by Inducing TLR2/NLRP3-Mediated M1-Like TAMs

Silencing Of Cxcr7 Gene Represses Growth And Invasion And Induces Apoptosis In Colorectal Cancer Through Erk And Beta-Arrestin Pathways

Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer

Mechanisms involved in biological behavior changes associated with Angptl4 expression in colon cancer cell lines.

Depletion of the Proteasome Subunit Psma7 Inhibits Colorectal Cancer Cell Tumorigenicity and Migration

Silencing CXCR6 Promotes Epithelial-Mesenchymal Transition and Invasion in Colorectal Cancer by Activating the VEGFA/PI3K/AKT/mTOR Pathway

IGFBP7 Plays a Potential Tumor Suppressor Role Against Colorectal Carcinogenesis with Its Expression Associated with DNA Hypomethylation of Exon 1

Expression of B7 Costimulation Molecules by Colorectal Cancer Cells Reduces Tumorigenicity and Induces Anti-Tumor Immunity

Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8+ T lymphocytes

Colorectal cancer cells suppress CD4+ T cells immunity through canonical Wnt signaling

Supplementary Figure 1 from KLF4-Mediated Negative Regulation of IFITM3 Expression Plays a Critical Role in Colon Cancer Pathogenesis

Activation of WNT7b autocrine eases metastasis of colorectal cancer via epithelial to mesenchymal transition and predicts poor prognosis

Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition

Expression of Interleukin-6 and Integrin ανβ6 in Colon Cancer: Association with Clinical Outcomes and Prognostic Implications

Why Rules are Complex: Real-Valued Probabilistic Logic Programs are not Fully Expressive

Supplementary Figure 7 from BATF2 Deficiency Promotes Progression in Human Colorectal Cancer Via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs

Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells

Aortitis caused by beta-lactamase producing Haemophilus influenzae type b.

B7-H3 promotes colorectal cancer angiogenesis through activating the NF-κB pathway to induce VEGFA expression